Michigan Medicine to help lead NIH study of extra COVID-19 vaccine dose in people with autoimmune disease

Participants will be followed for 13 months with preliminary results expected in November 2021.

Author | Noah Fromson

A Michigan Medicine physician will co-lead a National Institutes of Health study of antibody response to an additional dose of the COVID-19 vaccine in people with autoimmune diseases who did not present a strong immune response to the first round of authorized vaccination.

A COVID-19 vaccine given at Michigan Medicine. Credit: Michigan Medicine

The announcement comes just a few weeks after the FDA and Centers for Disease Control and Prevention recommended( that people who are moderately-to-severely immunocompromised receive a third dose of an mRNA COVID-19 vaccine. Despite making up less than 3% of the U.S. adult population, immunocompromised people account for nearly 45% of breakthrough COVID infections requiring hospitalization.

The trial will be co-led by Dinesh Khanna, M.B.B.S., M.Sc., the Frederick G.L. Huetwell professor of rheumatology and the director of the scleroderma program at Michigan Medicine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is funding the Phase 2 trial.

“Although the FDA has recently approved booster vaccines for immunocompromised patients under emergency use authorization, there are several advantages for patients to participate in this 12-month adaptive trial design,” Khanna said. “It allows us to carefully evaluate if the patients respond to the booster vaccine, continue to assess for durability of the vaccine over time and assess risk of flare of the underlying autoimmune disease.”

The trial will include approximately 600 adult participants with one of five autoimmune diseases:

  • Multiple Sclerosis
  • Pemphigus
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis

Trial participants, who will be followed for 13 months, must be taking immunosuppressive therapies and have demonstrated poor antibody response to an authorized COVID-19 vaccine regimen. The research team will also examine whether pausing immunosuppressive medication improves immune response to the booster shot.

“To hold or withhold the immunosuppressive therapies is an important issue for patients with autoimmune disease,” Khanna said. “On one hand, it may improve the response to the booster, and on the other hand, it may lead to disease flare. This trial will carefully evaluate this in a controlled fashion.”

For more information about the COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders trial, go to ClinicalTrials.gov and use NCT05000216 as an identifier.


Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Featured News & Stories pills doctor prescription patient
Health Lab
How one state beat national surgery opioid trends
Medication guidelines for post-surgical opioid prescribing were associated with a lower rate of long-term opioid use and much lower amounts of opioid prescription fills in Michigan compared with the rest of the U.S.
glowy balls images connected light green
Health Lab
Candida auris: The deadly fungus on the rise
Candida auris is a deadly fungus on the rise that the CDC has issues warnings about. A Michigan Medicine microbiologist and immunologist explains more about the pathogen.
backs of three people
Health Lab
When genetic testing can help the whole family
Genetic testing for hereditary conditions such as breast cancer can have implications for the whole family. Learn how genetic testing helped Cathleen Argyle and her family to uncover a rare mutation and how the Rogel Cancer Center provided advice and guidance throughout the process.
cancer cell
Health Lab
Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds
An artificial intelligence screening system called DeepGlioma predicts genetics of cancerous brain tumors in under 90 seconds.
pregnant women 3 blue and yellow background
Health Lab
Income affects maternal and infant health in somewhat unexpected ways
While higher income improves maternal and infant health over time, it’s not enough to offset the impact of race, according to new research. In addition, although higher-income mothers and their babies ultimately end up with better health outcomes, they actually start out with more difficulties. And regardless of wealth, maternal and infant health in the United States lags behind Sweden.
gif of people with spinal injuries walking and sun setting purple pink yellow grey
Health Lab
For spinal cord injuries, acceptance and commitment therapy aids in recovery
For spinal cord injuries, acceptance and commitment therapy aids in recovery.